An Overview of Optimal Endovascular Strategy in Treating the Femoropopliteal Artery: Mechanical, Biological, and Procedural Factors

Abstract

Treatment of the femoropopliteal (FP) artery remains a challenge to the endovascular specialist. Long-term patency is low with a high rate of target lesion revascularization. The true patency rate varies considerably between studies partly because there is a lack of uniform performance criteria and reporting standards in peripheral arterial interventions. Literature review supports three principles that emerge as important components of an optimal strategy in treating the FP artery: (1) improving vessel compliance and subsequently less dissections and bailout stenting, (2) reducing smooth muscle cell proliferation, and (3) protecting outflow vessels from distal embolization. In this overview, we examine current data that support the validity of this strategy.

Keywords

femoropopliteal artery - restenosis - atherectomy - drug-coated balloon - in-stent restenosis - distal embolization - tibial runoff

• References

• 1 Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag 2007; 3 (2) 229-234
• 2 Anderson PL, Gelijns A, Moskowitz A , et al. Understanding trends in inpatient surgical volume: vascular interventions, 1980–2000. J Vasc Surg 2004; 39 (6) 1200-1208
• 3 Kandarpa K, Becker GJ, Hunink MG , et al. Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: part I. J Vasc Interv Radiol 2001; 12 (6) 683-695
• 4 Laird JR. Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries. J Endovasc Ther 2006; 13 (Suppl. 02) II30-II40
• 5 Shammas NW. Optimal strategy in lower extremity peripheral percutaneous interventions: an interventionalist's perspective. Vasc Dis Manage 2009; 6: 36-40
• 6 Shammas NW, Coiner D, Shammas GA, Dippel EJ, Christensen L, Jerin M. Percutaneous lower-extremity arterial interventions with primary balloon angioplasty versus Silverhawk atherectomy and adjunctive balloon angioplasty: randomized trial. J Vasc Interv Radiol 2011; 22 (9) 1223-1228
• 7 Shammas NW, Lam R, Mustapha J , et al. Comparison of orbital atherectomy plus balloon angioplasty vs. balloon angioplasty alone in patients with critical limb ischemia: results of the calcium 360 randomized pilot trial. J Endovasc Ther 2012; 19 (4) 480-488
• 8 Gillessen T, Gillessen F, Sieberth H, Hanrath P, Heintz B. Age-related changes in the elastic properties of the aortic tree in normotensive patients: investigation by intravascular ultrasound. Eur J Med Res 1995; 1 (3) 144-148
• 9 Losordo DW, Rosenfield K, Pieczek A, Baker K, Harding M, Isner JM. How does angioplasty work? Serial analysis of human iliac arteries using intravascular ultrasound. Circulation 1992; 86 (6) 1845-1858
• 10 Shammas NW, Coiner D, Shammas GA, Christensen L, Dippel EJ, Jerin M. Distal embolic event protection using excimer laser ablation in peripheral vascular interventions: results of the DEEP EMBOLI registry. J Endovasc Ther 2009; 16 (2) 197-202
• 11 Shammas NW, Weissman NJ, Coiner D, Shammas GA, Dippel E, Jerin M. Treatment of subacute and chronic thrombotic occlusions of lower extremity peripheral arteries with the excimer laser: a feasibility study. Cardiovasc Revasc Med 2012; 13 (4) 211-214
• 12 Dave RM, Patlola R, Kollmeyer K , et al; CELLO Investigators. Excimer laser recanalization of femoropopliteal lesions and 1-year patency: results of the CELLO registry. J Endovasc Ther 2009; 16 (6) 665-675
• 13 Cotroneo AR, Pascali D, Iezzi R. Cutting balloon versus conventional balloon angioplasty in short femoropopliteal arterial stenoses. J Endovasc Ther 2008; 15 (3) 283-291
• 14 Albiero R, Silber S, Di Mario C , et al; RESCUT Investigators. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). J Am Coll Cardiol 2004; 43 (6) 943-949
• 15 Laird JR, Biamino G, McNamara T , et al. Cryoplasty for the treatment of femoropopliteal arterial disease: extended follow-up results. J Endovasc Ther 2006; 13 (Suppl. 02) II52-II59
• 16 Jahnke T, Mueller-Huelsbeck S, Charalambous N , et al. Prospective, randomized single-center trial to compare cryoplasty versus conventional angioplasty in the popliteal artery: midterm results of the COLD study. J Vasc Interv Radiol 2010; 21 (2) 186-194
• 17 Spiliopoulos S, Katsanos K, Karnabatidis D , et al. Cryoplasty versus conventional balloon angioplasty of the femoropopliteal artery in diabetic patients: long-term results from a prospective randomized single-center controlled trial. Cardiovasc Intervent Radiol 2010; 33 (5) 929-938
• 18 Schillinger M, Sabeti S, Loewe C , et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354 (18) 1879-1888
• 19 Laird JR, Katzen BT, Scheinert D , et al. RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 2010; 3 (3) 267-276
• 20 Schillinger M, Sabeti S, Dick P , et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007; 115 (21) 2745-2749
• 21 Laird JR, Katzen BT, Scheinert D , et al., RESILIENT Investigators. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther 2012; 19 (1) 1-9
• 22 Bosiers M, Deloose K, Callaert J , et al. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg 2011; 54 (4) 1042-1050
• 23 Iida O, Soga Y, Hirano K , et al. Long-term outcomes and risk stratification of patency following nitinol stenting in the femoropopliteal segment: retrospective multicenter analysis. J Endovasc Ther 2011; 18 (6) 753-761
• 24 Schlager O, Dick P, Sabeti S , et al. Long-segment SFA stenting—the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther 2005; 12 (6) 676-684
• 25 Scheinert D, Scheinert S, Sax J , et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005; 45 (2) 312-315
• 26 Shammas NW, Dippel EJ, Shammas G, Gayton L, Coiner D, Jerin M. Dethrombosis of the lower extremity arteries using the power-pulse spray technique in patients with recent onset thrombotic occlusions: results of the DETHROMBOSIS Registry. J Endovasc Ther 2008; 15 (5) 570-579
• 27 Shammas NW, Weissman NJ, Coiner D, Shammas GA, Dippel E, Jerin M. Treatment of subacute and chronic thrombotic occlusions of lower extremity peripheral arteries with the excimer laser: a feasibility study. Cardiovasc Revasc Med 2012; 13 (4) 211-214
• 28 Norgren L, Hiatt WR, Dormandy JA , et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl. 01) S1-S75
• 29 Shammas NW, Coiner D, Shammas G, Jerin M. Predictors of provisional stenting in patients undergoing lower extremity arterial interventions. Int J Angiol 2011; 20 (2) 95-100
• 30 Kandarpa K, Becker GJ, Hunink MG , et al. Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: part I. J Vasc Interv Radiol 2001; 12 (6) 683-695
• 31 Dubé H, Clifford AG, Barry CM, Schwarten DE, Schwartz LB. Comparison of the vascular responses to balloon-expandable stenting in the coronary and peripheral circulations: long-term results in an animal model using the TriMaxx stent. J Vasc Surg 2007; 45 (4) 821-827
• 32 Schillinger M, Minar E. Restenosis after percutaneous angioplasty: the role of vascular inflammation. Vasc Health Risk Manag 2005; 1 (1) 73-78
• 33 Schillinger M, Exner M, Mlekusch W , et al. Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis. Radiology 2002; 225 (1) 21-26
• 34 Schillinger M, Exner M, Mlekusch W , et al. Inflammatory response to stent implantation: differences in femoropopliteal, iliac, and carotid arteries. Radiology 2002; 224 (2) 529-535
• 35 Schillinger M, Exner M, Mlekusch W , et al. Endovascular revascularization below the knee: 6-month results and predictive value of C-reactive protein level. Radiology 2003; 227 (2) 419-425
• 36 Hunink MG, Donaldson MC, Meyerovitz MF , et al. Risks and benefits of femoropopliteal percutaneous balloon angioplasty. J Vasc Surg 1993; 17 (1) 183-192 , discussion 192–194
• 37 Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJ, Lumsden AB. Percutaneous superficial femoral artery interventions for claudication—does runoff matter?. Ann Vasc Surg 2008; 22 (6) 790-798 [Epub ahead of print]
• 38 Gallino A, Mahler F, Probst P, Nachbur B. Percutaneous transluminal angioplasty of the arteries of the lower limbs: a 5 year follow-up. Circulation 1984; 70 (4) 619-623
• 39 Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation 1991; 83 (2, Suppl): I70-I80
• 40 Zeller T, Rastan A, Sixt S , et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol 2006; 48 (8) 1573-1578
• 41 Laird Jr JR, Yeo KK, Rocha-Singh K , et al. Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE Study. Catheter Cardiovasc Interv 2012; 80 (5) 852-859 [Epub ahead of print]
• 42 PATENT trial. Photo-ablation using the Turbo-Booster and excimer laser for in-stent restenosis treatment study. Presented at LINC 2012 at the Leipzig Interventional Course, in Leipzig, Germany. Article online in Endovascular today http://www.bmctoday.net/evtoday/2012/01/article.asp?f=interim-results-presented-for-spectranetics-patent-study
• 43 Shammas NW, Shammas GA, Hafez A, Kelly R, Reynolds E, Shammas AN. Safety and One-Year revascularization outcome of excimer laser ablation therapy in treating in-stent restenosis of femoropopliteal arteries: a retrospective review from a single center. Cardiovasc Revasc Med 2012; 13: 341-344
• 44 Wolfram RM, Budinsky AC, Pokrajac B, Pötter R, Minar E. Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery—the Vienna experience. Radiology 2005; 236 (1) 338-342
• 45 Diehm N, Silvestro A, Do DD , et al. Endovascular brachytherapy after femoropopliteal balloon angioplasty fails to show robust clinical benefit over time. J Endovasc Ther 2005; 12 (6) 723-730
• 46 Amighi J, Schillinger M, Dick P , et al. De novo superficial femoropopliteal artery lesions: peripheral cutting balloon angioplasty and restenosis rates–randomized controlled trial. Radiology 2008; 248: 297-302
• 47 Scheinert D, Laird Jr JR, Schröder M, Steinkamp H, Balzer JO, Biamino G. Excimer laser-assisted recanalization of long, chronic superficial femoral artery occlusions. J Endovasc Ther 2001; 8 (2) 156-166
• 48 Steinkamp HJ, Wissgott C, Rademaker J , et al. Short (1–10 cm) superficial femoral artery occlusions: results of treatment with excimer laser angioplasty. Cardiovasc Intervent Radiol 2002; 25 (5) 388-396
• 49 Stoner MC, deFreitas DJ, Phade SV, Parker FM, Bogey WM, Powell S. Mid-term results with laser atherectomy in the treatment of infrainguinal occlusive disease. J Vasc Surg 2007; 46 (2) 289-295
• 50 Banerjee S, Das TS, Abu-Fadel MS , et al. Pilot trial of cryoplasty or conventional balloon post-dilation of nitinol tents for revascularization of peripheral arterial segments: the COBRA trial. J Am Coll Cardiol 2012; 60 (15) 1352-1359
• 51 Yiu WK, Cheng SW, Sumpio BE. Vascular smooth muscle cell apoptosis induced by “supercooling” and rewarming. J Vasc Interv Radiol 2006; 17 (12) 1971-1977
• 52 Tepe G, Zeller T, Albrecht T , et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008; 358 (7) 689-699
• 53 Werk M, Langner S, Reinkensmeier B , et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008; 118 (13) 1358-1365
• 54 Duda SH, Bosiers M, Lammer J , et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006; 13 (6) 701-710
• 55 Duda SH, Bosiers M, Lammer J , et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005; 16 (3) 331-338
• 56 Dake MD, Scheinert D, Tepe G , et al.; Zilver PTX Single-Arm Study Investigators. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther 2011; 18 (5) 613-623
• 57 Dake MD, Ansel GM, Jaff MR , et al.; Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011; 4 (5) 495-504
• 58 Herdeg C, Göhring-Frischholz K, Haase KK , et al. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation. Circ Cardiovasc Interv 2009; 2 (4) 294-301
• 59 Ihnat DM, Duong ST, Taylor ZC , et al. Contemporary outcomes after superficial femoral artery angioplasty and stenting: the influence of TASC classification and runoff score. J Vasc Surg 2008; 47 (5) 967-974
• 60 Lee JJ, Katz SG. The number of patent tibial vessels does not influence primary patency after nitinol stenting of the femoral and popliteal arteries. J Vasc Surg 2012; 55 (4) 994-1000 , discussion 1000
• 61 Salapura V, Blinc A, Kozak M , et al. Infrapopliteal run-off and the outcome of femoropopliteal percutaneous transluminal angioplasty. Vasa 2010; 39 (2) 159-168
• 62 Siablis D, Karnabatidis D, Katsanos K, Ravazoula P, Kraniotis P, Kagadis GC. Outflow protection filters during percutaneous recanalization of lower extremities' arterial occlusions: a pilot study. Eur J Radiol 2005; 55 (2) 243-249
• 63 Suri R, Wholey MH, Postoak D, Hagino RT, Toursarkissian B. Distal embolic protection during femoropopliteal atherectomy. Catheter Cardiovasc Interv 2006; 67 (3) 417-422
• 64 Karnabatidis D, Katsanos K, Kagadis GC , et al. Distal embolism during percutaneous revascularization of infra-aortic arterial occlusive disease: an underestimated phenomenon. J Endovasc Ther 2006; 13 (3) 269-280
• 65 Shammas NW, Dippel EJ, Coiner D, Shammas GA, Jerin M, Kumar A. Preventing lower extremity distal embolization using embolic filter protection: results of the PROTECT registry. J Endovasc Ther 2008; 15 (3) 270-276
• 66 Allie DE, Ingraldi A, Patlola RR, Hebert CJ, Walker CM. Clinical insights into the use of embolic protection devices during lower extremity peripheral vascular interventions. J Invasive Cardiol 2009; 21 (8) 418-422
• 67 Shammas NW, Shammas GA, Dippel EJ, Jerin M, Shammas WJ. Predictors of distal embolization in peripheral percutaneous interventions: a report from a large peripheral vascular registry. J Invasive Cardiol 2009; 21 (12) 628-631
• 68 Lam RC, Shah S, Faries PL, McKinsey JF, Kent KC, Morrissey NJ. Incidence and clinical significance of distal embolization during percutaneous interventions involving the superficial femoral artery. J Vasc Surg 2007; 46 (6) 1155-1159
• 69 Shammas NW, Shammas GA, Dippel EJ, Jerin M. Intraprocedural outcomes following distal lower extremity embolization in patients undergoing peripheral percutaneous interventions. Vasc Dis Manage 2009; 6: 58-61
• 70 Covidien's SpiderFX Embolic Protection Device Approved for Use in Lower Extremities. Endovascular Today. http://bmctoday.net/evtoday/2011/11/article.asp?f=covidiens-spiderfx-embolic-protection-device-approved-for-use-in-lower-extremities
• 71 Zankar A, Brilakis ES, Banerjee S. Embolic capture angioplasty of lower extremity lesion following distal embolization. Cardiovasc Revasc Med 2011; 12 (5) 337-340
• 72 Shammas NW. Commentary: balloon angioplasty with built-in embolic protection mechanism: the dual role of the proteus balloon. J Endovasc Ther 2012; 19 (5) 617-619
• 73 Schillinger M, Minar E. Claudication: treatment options for femoropopliteal disease. Prog Cardiovasc Dis 2011; 54 (1) 41-46
• 74 Lin PH, Weakley SM, Kougias P. How to interpret data from the superficial femoral artery stenting trials and registries. Semin Vasc Surg 2010; 23 (3) 138-147
• 75 Ansel GM, Lumsden AB. Evolving modalities for femoropopliteal interventions. J Endovasc Ther 2009; 16 (2) (Suppl. 02) II82-II97
• 76 Lumsden AB, Davies MG, Peden EK. Medical and endovascular management of critical limb ischemia. J Endovasc Ther 2009; 16 (2) (Suppl. 02) II31-II62
• 77 Schillinger M, Minar E. Past, present and future of femoropopliteal stenting. J Endovasc Ther 2009; 16 (Suppl. 01) I147-I152
• 78 Nguyen MC, Garcia LA. Recent advances in atherectomy and devices for treatment of infra-inguinal arterial occlusive disease. J Cardiovasc Surg (Torino) 2008; 49 (2) 167-177